interferon der alte und neue Biotechwert - 500 Beiträge pro Seite

[trackcrack]

Hallo Leute !!

Wenn Ihr aktuelle NEWS zu Interferon haben wollt, dann schaut doch mal nach unter www.nasdaq.com- companynews.

Hier tut sich in letzter Zeit so Einiges !!!

u. A. ist hier auch der letzte Quaterreport erhältlich. Außerdem sind einige interessante Neuigkeiten in Bezug auf Beteiligungen und Futures zu erfahren.

Ich selber verfolge Interferon seit ca. 1997 und habe auch alle LOWS mitgemacht. ABER wenn Ihr den Chart der letzten Jahre anseht (incl. REVERSESPLIT !!!), dan ist ja wohl offensichtlich, daß INTERFERON noch lange nicht tot ist, sondern nur darauf wartet von Investoren entdeckt zu werden.

Ich persönlich glaube immer noch daran, daß Interferon in nicht allzu ferner Zukunft an die anderen Biotechwerte anknüpfen kann, da nach der aktuellen NEWS-Lage einige Überraschungen im "FEUER" sind.

Kurse um 2-3US$ in den nächsten Monaten würden mich daher nicht überraschen. Außerdem zeigt ja die Vergangenheit, daß Kurssprünge bei Interferon immer sehr sehr kurzfristig und heftig ausfallen.

HINWEIS: Ab ca. 14:00 Uhr MEZ werden vorbörsliche Kurse bei www.stockhouse.com angezeigt (siehe BID/ASK).

Good luck

TRACKCRACK

[Aktiensurfer]

Du hast Recht, TRACKCRACK.
Interferon könnte demnächst wieder "auferstehen".
Ich hatte die eigentlich schon für tot erklärt....
Gruß
Aktiensurfer

[Rabbithole]

HI zusammen,

ich habe mir Interferon nochnicht näher anschauen können, aber Reverse-Splits sind in meinen Augen nichts Gutes.

Ein Pennystock wird damit einfach mal optisch teurer gemacht...

Das ist jetzt aber eine ganz allgemeine Aussage und hat nichts mit den Aussichten von Interferon zu tun.

Rabbithole

[trackcrack]

Du hast Recht, Reversesplits haben im Allgemeinen einen negativen Hintergrund. Der Hauptgrund hierfür ist meistens (bei Nasdaq-Werten) den Kurs über das Nasdaq-Limit von 1,00$ zu heben um einem Delisting zu entgehen.
Grundsätzlich sagt es aber nicht aus, daß eine Firma kurz vor der Pleite steht. Im Falle von Interferon war der reversesplit ein "Kapitalmaßnahme".
Das heißt, daß das Unternehmen seine Eigenkapitalstruktur verändert hat. Die nachfolgenden Maßnahmen geben mehr Aufschluß über diesen Reversesplit.
So hat Interferon in den vergangenen 2 Jahren im Rahmen einer Privatplazierung von neuen Aktien die Steuerschulden beglichen. Zum anderen hat Interferon seine Eigenkapitalstrutur wieder ins Lot gebracht.
Aber nichts desto trotz schaut Euch doch mal an welche Beteiligungen in den letzten Monaten eingegangen wurden. Beispiel hierzu die Beteiligung an Metacine (siehe auch unter www.nasdaq.com / company news.
Ich denke, daß Interferon diese Beteiligungen nicht aus Spaß an Freude erworben hat.
Warum ? Tja Interferon ist ja nicht ein neuer unererfahrener Wert sondern Interferon gibt es schon seit Anfang der Neunziger Jahre. Damals hatten sie auch wesentich höhere Kurse.
Aber zum Vergleich könnt Ihr Euch ja mal einige große Biotechunternehmen in der Vergangenheit ansehen. Auch diese Unternehmen fingen mal bei 1-2$ an.
Die Kursgewinne bei solchen Biotechunternehmen explodieren manchmal von heute auf morgen. Ausgangspunkt hierfür sind u. a. Zulassungen für neue Medikamente, die die Stufe 3 der FDA passiert haben. Interferon hat einige Neuentwicklungen in den Stufen 1 - 2 laufen.

ABER Vorsicht !!! Gerade bei Biotechwerten ist das Risiko von Totalverlusten sehr hoch, gerade dann wenn ein Unternehmen nur wenige Produkte in der Pipeline hat !!!

Interferon ist zwar eine realtiv "alter" Wert aber auch nicht vor einer Pleite gefeit.

Erfahrung ist zwar sehr gut aber auch manchmal gefährlich.

Meiner Einschätzung nach hat aber Interferon eine äußerst interessant Zukunft vor sich.

Hier einige Artikel aus der letzten NEWS-Runde:

Interferon (Kürzel IFSC, www.nasdaq.com)

1. Interferon Sciences Buys 43% Of Anti-Cancer Vaccine Maker

NEW BRUNSWICK, N.J.-(Dow Jones)- Interferon Sciences Inc. (IFSC) exercised its option to buy 43% of the common stock of closely-held Metacine Inc., a developer of anti-cancer vaccines based on dendritic cell technology.
Interferon Sciences said in a press release that it also received a five-year warrant to purchase an additional 9% of Metacine`s shares at an increased value.

Terms weren`t disclosed.

Metacine`s technology was developed during a 10-year, $25 million research effort by a team of six scientists at the University of Pittsburgh Medical Center. A Phase I clinical trial is currently underway at the university for treatment of melanoma, the deadliest form of skin cancer. In this trial, dendritic cells isolated from the patient`s blood are pulsed with multiple melanoma antigens (substances capable of inducing an immune response) to generate a "pulsed antigen" vaccine. The pulsed dendritic cells are then reinjected into the patient to stimulate the immune system to attack tumor cells that display these antigens.

This trial follows an already completed 28-patient Phase I trial in which safety and immune response to the specific antigens used in the trial was demonstrated. Several additional Phase I trials are being planned.

To date, a general lack of significant side effects in human clinical trials has been observed by Metacine, and by others investigating dendritic cell-based therapy.

Interferon Sciences is a biopharmaceutical company.

(This story was originally published by Dow Jones Newswires)


2. Interferon Sciences Receives Exclusive License From Mayo Foundation for Medical Education and Research for Novel Approach to Prevent Recurrence of Tumors After Cancer Surgery
NEW BRUNSWICK, N.J.--(BW HealthWire)--May 14, 2001--


ISI Will Provide Study Drug And Fund Clinical Research That Could Enhance The Outcome Of Cancer Surgeries

Interferon Sciences, Inc. (ISI) (OTC-BB:IFSC) announced that it has signed an exclusive technology license agreement with Mayo Foundation for Medical Education and Research, of Rochester, MN, for the rights to technology under investigation for preventing the recurrence of cancer after surgical removal of tumors.

The approach, referred to as neo-adjuvant immunotherapy with interferon, is being developed at Mayo Clinic by Svetomir N. Markovic, M.D, Ph.D., Assistant Professor of Oncology at Mayo Medical School. It is based upon encouraging preclinical studies in which natural murine (mouse) leukocyte interferon was used to pre-treat mice in order to stimulate their immune systems prior to surgical resection of their tumors (murine melanoma).

The animal studies showed that short duration pre-treatment with interferon in the neo-adjuvant protocol significantly increased the percentage of survival compared to untreated controls (56% vs. 0%). Animals treated with interferon for the same duration immediately after surgery (adjuvant therapy) did no better than the untreated controls. It is unknown whether comparable results can be achieved in humans.

As part of the collaboration with Mayo, Interferon Sciences will fund a clinical trial entitled "Identification of an Immunostimulatory Dose of Natural Interferon (Phase A) and Its Impact on Clinical Outcome (Phase B) in Patients with Melanoma", and supply its human leukocyte derived alpha interferon as the study drug.

With regard to this study, Dr. Markovic commented, "I am looking forward to conducting this trial to continue our investigation in humans of the potential of this exciting new immunotherapeutic approach -- neo-adjuvant natural interferon for the prevention of metastatic recurrences."

"If this neo-adjuvant immunotherapy approach with human leukocyte derived alpha interferon is ultimately found to be successful in extending the disease-free interval after surgery, it would not only extend survival of these patients, but also enhance their quality of life," commented James R. Knill, M.D., Vice President of Medical Affairs for Interferon Sciences.

Interferon Sciences, Inc. is a biopharmaceutical company engaged in the study, manufacture and sale of pharmaceutical products based on its highly purified, natural-source, multi-species alpha interferon. The Company`s ALFERON N Injection(R) (Interferon Alfa-n3) product has been approved by the United States Food and Drug Administration for the treatment of certain types of genital warts, and is being studied for potential use in other indications, including cancer and multiple sclerosis. In addition, the Company is seeking to enter into collaborations with companies in the areas of cancer, infectious diseases, and immunology. The Company`s strategy is to utilize its expertise in regulatory affairs, clinical trials, manufacturing, and research and development to acquire equity participations in early stage companies. The Company recently announced the acquisition of 43% of Metacine, Inc., a company developing anti-cancer vaccines based on dendritic cell technology.

The forward-looking statements contained herein reflect ISI management`s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of ISI, including, those risks and uncertainties detailed in the Company`s periodic reports and registration statements filed with the Securities and Exchange Commission. Interferon Sciences, Inc...Advancing immunotherapy naturally


Machts gut


Trackcrack

[frank55]

komisch realtimekurs in den usa,0,47 dollar,aber bekomme in deutschland keine zu 0,55 euro

[trackcrack]

Hallo Leute,

es kommt was auf uns zu ....

Seht Euch unbedingt in den nächsten Tagen die NEWS zu Interferon bei www.nasdaq.com, IFSC, NEWS an.... bleibt dabei und sammelt ein (wenn möglich !!).

Gruß

trackcrack

[erkilein]

welche art news erwartest du? phasenergebnisse?

[trackcrack]

Ich erwarte NEWS in Hinblick auf folgende Meldung von Interferon:
Data On the Use of Interferon Alfa-n3 in the Treatment of Multiple Sclerosis Presented At the XVII World Congress of Neurology Meeting

NEW BRUNSWICK, N.J.--(BW HealthWire)--June 25, 2001--Interferon Sciences, Inc. (ISI) (OTC-BB:IFSC) announced that a poster reporting on a retrospective evaluation entitled, "Interferon alfa-n3 (Alferon N) Reduces Enhancing Gadolinium Brain Lesions in Multiple Sclerosis" was presented at the XVII World Congress of Neurology Meeting in London, by Professor William Sheremata, Chief of the Multiple Sclerosis/Neuroimmunology Center of the University of Miami School of Medicine.

Evaluation Results

Brain magnetic resonance imaging (MRI) was performed in 69 multiple sclerosis (MS) patients either treated with interferon alfa-n3 or untreated as control. The images revealed the presence of gadolinium enhanced (Gd+) lesions in the brain in 2 out of 31 patients (6%) treated with interferon alfa-n3 for 3-6 months, as compared to 14 out of 38 patients (37%) in the untreated group. Gd+ lesions in 1 of the 2 Gd+ patients in the interferon alfa-n3 group were found to be due to an arterio-venous malformation of the corpus callosum, and not MS-related new active lesions. Gd+ allows the earliest identification of new or "active" lesions in the brain because it only enters the brain where there is a breakdown in the blood brain barrier. Following the initial assessment, no other patients exhibited new active brain lesions with continued interferon alfa-n3 therapy.

Expanded Disability Status Scale (EDSS) scores were recorded for these patients over a mean of 11 months of follow-up. In this evaluation, disability decreased in the interferon alfa-n3 treated group since EDSS scores decreased from 4.8 to 3.4, while these scores in the untreated group increased from 3.8 to 4.5. The scale of EDSS scores ranges from 0 for a normal neurological examination to a score of 10 for death due to multiple sclerosis.

Background

The majority of treated patients included in the interferon alfa-n3 treated group had received subcutaneous injections of interferon alfa-n3 after adverse reactions were experienced from treatment with other agents. These included MS patients who had suffered from prominent injection site reactions or other side effects from interferon beta-1b (Betaseron(R)). Interferon alfa-n3 was also used in patients with very active MS, rapidly progressive disease, or those with advanced disability who were judged unlikely to benefit from or tolerate Betaseron.

Brain MRI with Gd+ was performed in 69 MS patients, 38 who declined treatment (untreated group) and 31 treated subcutaneously with interferon alfa-n3. MRI allows objective evaluation of disease progression in MS.

In this study, a retrospective evaluation of brain disease in MS utilizing patient records and evaluating MRI scans was performed. MRI scan records documenting disease were identified in consecutive MS patient`s records from a master list. Clerical staff assembled this list without regard to factors other than the patient`s treatment status. Both patient records and recorded images were reviewed. Reports were identified and information regarding the use of gadolinium enhancement and the MRI studies were retrieved. Images were subsequently evaluated and the presence of Gd+ lesions in images from patients with clinically definite MS was confirmed.

This retrospective evaluation does not constitute a prospective clinical study of the type needed to obtain regulatory approval, and does not indicate that interferon alfa-n3 will be shown to be effective if such clinical studies are performed. However, based in part upon these encouraging findings, the Company has begun seeking a corporate partner to further assess the use of its interferon alfa-n3 product as a potential treatment in patients afflicted with MS.


Gruß

trackcrack